Neuroimaging Findings of Organic Acidemias and Aminoacidopathies by Reddy, Nihaal et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Neuroimaging Findings of Organic Acidemias and Aminoacidopathies
Reddy, Nihaal; Calloni, Sonia F; Vernon, Hilary J; Boltshauser, Eugen; Huisman, Thierry A G M;
Soares, Bruno P
Abstract: Although individual cases of inherited metabolic disorders are rare, overall they account for a
substantial number of disorders affecting the central nervous system. Organic acidemias and aminoaci-
dopathies include a variety of inborn errors of metabolism that are caused by defects in the intermediary
metabolic pathways of carbohydrates, amino acids, and fatty acid oxidation. These defects can lead to the
abnormal accumulation of organic acids and amino acids in multiple organs, including the brain. Early
diagnosis is mandatory to initiate therapy and prevent permanent long-term neurologic impairments or
death. Neuroimaging findings can be nonspecific, and metabolism- and genetics-based laboratory in-
vestigations are needed to confirm the diagnosis. However, neuroimaging has a key role in guiding the
diagnostic workup. The findings at conventional and advanced magnetic resonance imaging may suggest
the correct diagnosis, help narrow the differential diagnosis, and consequently facilitate early initiation of
targeted metabolism- and genetics-based laboratory investigations and treatment. Neuroimaging may be
especially helpful for distinguishing organic acidemias and aminoacidopathies from other more common
diseases with similar manifestations, such as hypoxic-ischemic injury and neonatal sepsis. Therefore, it
is important that radiologists, neuroradiologists, pediatric neuroradiologists, and clinicians are familiar
with the neuroimaging findings of organic acidemias and aminoacidopathies. RSNA, 2018.
DOI: https://doi.org/10.1148/rg.2018170042
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-162001
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Reddy, Nihaal; Calloni, Sonia F; Vernon, Hilary J; Boltshauser, Eugen; Huisman, Thierry A G M; Soares,
Bruno P (2018). Neuroimaging Findings of Organic Acidemias and Aminoacidopathies. Radiographics,
38(3):912-931.
DOI: https://doi.org/10.1148/rg.2018170042
P
ED
IA
T
R
IC
 I
M
A
G
IN
G 912
Neuroimaging Findings of Organic 
Acidemias and Aminoacidopathies1
Although individual cases of inherited metabolic disorders are rare, 
overall they account for a substantial number of disorders affecting 
the central nervous system. Organic acidemias and aminoacidopa-
thies include a variety of inborn errors of metabolism that are 
caused by defects in the intermediary metabolic pathways of carbo-
hydrates, amino acids, and fatty acid oxidation. These defects can 
lead to the abnormal accumulation of organic acids and amino ac-
ids in multiple organs, including the brain. Early diagnosis is man-
datory to initiate therapy and prevent permanent long-term neuro-
logic impairments or death. Neuroimaging findings can be nonspe-
cific, and metabolism- and genetics-based laboratory investigations 
are needed to confirm the diagnosis. However, neuroimaging has a 
key role in guiding the diagnostic workup. The findings at conven-
tional and advanced magnetic resonance imaging may suggest the 
correct diagnosis, help narrow the differential diagnosis, and con-
sequently facilitate early initiation of targeted metabolism- and ge-
netics-based laboratory investigations and treatment. Neuroimaging 
may be especially helpful for distinguishing organic acidemias and 
aminoacidopathies from other more common diseases with similar 
manifestations, such as hypoxic-ischemic injury and neonatal sepsis. 
Therefore, it is important that radiologists, neuroradiologists, pedi-
atric neuroradiologists, and clinicians are familiar with the neuro-
imaging findings of organic acidemias and aminoacidopathies.
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After completing this journal-based SA-CME activity, participants will be able to:
 ■Discuss the importance of rendering a precise diagnosis of inborn errors of metabo-
lism—organic acidemias and aminoacidopathies in particular.
 ■ Identify the neuroimaging findings of pediatric organic acidemias and aminoacidop-
athies.
 ■Describe the important clinical, genetic, and prognostic factors of each entity related 
to organic acidemias and aminoacidopathies and thus better address these entities 
with clinicians and patients.
See www.rsna.org/education/search/RG.
SA-CME LEARNING OBJECTIVES
Introduction
Although inborn errors of metabolism are rare diseases individu-
ally, collectively they account for a remarkable number of disor-
ders of the pediatric central nervous system, with an aggregate 
incidence of one in 1000 newborns (1,2). The majority of inborn 
errors of metabolism in newborns and infants are organic acid 
and amino acid disorders. The accumulation of amino acids in the 
bloodstream and the urinary excretion of these acids are termed 
acidemia and aciduria, respectively. These disorders are also known 
This copy is for personal use only. To order printed copies, contact reprints@rsna.org
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curs at a later age (Table 1), can be variable and 
largely asymptomatic (1). Symptoms charac-
teristically occur postnatally after an interval of 
apparent good health. A catabolic episode such as 
infection, refusal to feed, dehydration, or exces-
sive protein or carbohydrate load can trigger 
the onset of symptoms and sudden neurologic 
deterioration. Typical symptoms at presentation 
include irritability, feeding difficulty, uncoordi-
nated sucking or swallowing, abnormal muscle 
tone, persistent and severe vomiting, and seizures 
(Table 2). Vomiting may be misinterpreted as a 
manifestion of hypertrophic pyloric stenosis. In 
severely affected children, disease progression 
may lead to coma, episodic apnea, and death. In 
other children, symptoms may partially resolve 
and then recur after days or weeks.
Clinical examination of children with organic 
acidemias and aminoacidopathies during their 
well state typically reveals nonspecific find-
ings, with a few notable exceptions (1). Corneal 
clouding, cataract, optic nerve abnormalities, and 
macular or retinal pigmentary changes may be 
helpful in establishing a diagnosis. Hepatomegaly 
may be present. An unusual odor of the child’s 
body, cerumen, or urine has been associated with 
several organic acidemias and other amino acid 
metabolism disorders.
Diagnostic Workup of Organic 
Acidemias and Aminoacidopathies  
in Children
Once a patient’s history and clinical presentation 
suggest an organic acidemia or aminoacidopa-
thy, the diagnostic workup and general support-
ive measures should be started simultaneously. 
Although many of these disorders ultimately can 
be detected with newborn screening, neuroimag-
ing should not be delayed until laboratory results 
are available or known because it may yield early 
crucial clues to the diagnosis and lead to the initia-
tion of treatment to prevent or limit irreversible 
injury. Laboratory analyses of blood, urine, and/or 
cerebrospinal fluid (CSF) also have an important 
diagnostic role. These evaluations should include 
quantitative assessment of plasma amino acid, 
urine organic acid, and plasma carnitine (free and 
total) levels, and identification and quantification 
of acylcarnitines in plasma or serum.
Other basic analyses, including measurements 
of the hematologic cell count and electrolyte, 
blood glucose, liver transaminase, ammonia, lactic 
acid, pyruvic acid, and blood gas (venous or arte-
rial) levels, should be performed to determine the 
acid-base status and, if applicable, the cause of the 
abnormal status (respiratory or metabolic). In ad-
dition, the homocysteine concentration may reveal 
information about the cobalamin metabolism. 
as organic acidopathies and aminoacidopathies. 
Affected newborns are usually asymptomatic 
at birth; however, earlier clinical onset occurs 
in children who have more profound enzymatic 
defects. Overall, the age of affected individu-
als at disease onset ranges from a few hours to 
months after birth. A correct diagnosis and the 
institution of appropriate therapy are critical 
to improving the long-term neurologic out-
come and preventing death. Neuroimaging has 
an important role in the diagnostic workup of 
children suspected of having inborn errors of 
metabolism. The findings may be diagnostic or 
help to narrow the differential diagnosis and 
guide further diagnostic examinations.
In this article, we review the neuroimaging 
findings of organic acidemias and aminoacidopa-
thies, beginning with a summary of the clinical 
manifestations and diagnostic workup of these 
disorders. The Online Mendelian Inheritance 
in Man (OMIM) phenotype number for each 
described acidemia and aminoacidopathy, as 
listed in the OMIM catalog of genetic disorders, 
is provided for reference.
Clinical Manifestations of Organic 
Acidemias and Aminoacidopathies  
in Children
Clinical phenotypes, which include acute life-
threatening metabolic decompensation or crisis 
disorders that occur during the neonatal period 
and episodic or chronic deterioration that oc-
TEACHING POINTS
 ■ Symptoms characteristically occur postnatally after an interval 
of apparent good health. A catabolic episode such as infec-
tion, refusal to feed, dehydration, or excessive protein or car-
bohydrate load can trigger the onset of symptoms and sud-
den neurologic deterioration.
 ■ An increased frequency of intracranial hemorrhage—seen as 
subarachnoid, intra- or periventricular, cerebellar, and diffuse 
petechial lesions in the white matter—has been reported with 
isovaleric acidemia.
 ■ The 1H MR spectrum in Canavan disease is pathognomonic 
and shows a markedly increased NAA peak level in both mild 
and severe cases and during the neonatal period, with the re-
maining MR imaging findings usually being normal.
 ■ With GA1, subdural hematomas can be seen in symptomatic 
and asymptomatic patients, even during the immediate post-
natal period. These hematomas can occur, sometimes repeat-
edly, with minimal trauma, mimicking abusive head trauma. 
The hematomas are presumably related to the rupture of 
bridging veins in the presence of cerebral atrophy.
 ■ With nonketotic hyperglycinemia, 1H MR spectroscopy will re-
veal a striking increase in the glycine peak level at 3.55 ppm. 
Because the glycine peak cannot be distinguished from the 
normal myo-inositol peak on short-echo MR spectra, the el-
evation in glycine concentration might be best evaluated by 
using long-echo 1H MR spectra.
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can be suggestive of metabolic brain injury (3). 
Magnetic resonance (MR) imaging is the most 
sensitive and specific neuroimaging tool for de-
tection and assessment of organic acidemias and 
aminoacidopathies (4). Moreover, the integra-
tion of advanced MR imaging techniques such 
as diffusion-weighted imaging, diffusion-tensor 
imaging, and hydrogen 1 (1H) MR spectroscopy 
enables more accurate and reliable anatomic-
functional diagnoses. Diffusion-weighted imaging 
depicts early parenchymal changes and enables 
characterization of different types of parenchymal 
edema—mainly cytotoxic (ie, with low apparent 
diffusion coefficient [ADC] values) and vaso-
genic (ie, with increased ADC values) edema 
(5). Diffusion-tensor imaging can be used to 
characterize the directionality of water motion by 
means of measurement of the full tensor of the 
diffusion. Qualitative and quantitative 1H-MR 
spectroscopic examinations are powerful non-
invasive tools that can be used to study various 
brain metabolites. 
Additional testing may include measurements 
of CSF and plasma glycine levels—which are el-
evated in persons with glycine encephalopathy—
and measurements of the urine S-sulfocysteine 
concentration, which is elevated in individuals 
with sulfite oxidase deficiency or molybdenum 
cofactor deficiency. It is preferable to collect 
samples during an acute episode, when metabolic 
abnormalities are most pronounced. The storage 
of adequate amounts of plasma, urine, blood (on 
filter paper), and CSF is important, and all bio-
logic data should be collected at the same time, if 
possible (2). Specific enzyme assays and/or mo-
lecular studies to identify specific gene mutations 
can be performed thereafter.
Neuroimaging of Organic Acidemias 
and Aminoacidopathies in Children
In newborns, head ultrasonography is a reliable 
first-line imaging modality that can be performed 
at the bedside for early detection of brain edema 
or altered white matter echogenicity, which 
Table 1: Timing of Manifestion of Pediatric Organic Acidemias and Aminoacidopathies
Disease* Neonatal Period Early Infantile Period Late Infantile Period Juvenile Period
Propionic acidemia ++ + + +
MMA ++ + - -
Isovaleric acidemia ++ + - -
MCCD - ++ ++ -
Biotinidase deficiency - ++ + ++
HSD ++ + + -
bKD ++ + - -
Canavan disease - ++ - -
GA1 - ++ ++ -
L2HGA - - ++ +
D2HGA ++ ++ - -
5-Oxoprolinuria ++ ++ - -
3HBA ++ - - -
3HMGD ++ - - -
Phenylketonuria ++ - - -
TYRSN1 ++ - - -
MSUD ++ - + -
NKH ++ - - -
CBSD - ++ + -
MTHFRD - ++ + +
SOD and MOCD ++ - - -
Note.—The organic acidemias and aminoacidopathies that are rare (+), common (++), or not present (or no 
information is available) (-) during the given periods are listed.
*βKD = β-ketothiolase deficiency, CBSD = cystathionine β-synthase deficiency, D2HGA = d-2-hydroxyglutaric 
aciduria, GA1 = glutaric aciduria type 1, HSD = holocarboxylase synthetase deficiency, L2HGA = l-2-hydrox-
yglutaric aciduria, MCCD = 3-methylcrotonyl coenzyme A carboxylase deficiency, MMA = methylmalonic 
acidemia, MOCD = molybdenum cofactor deficiency, MSUD = maple syrup urine disease, MTHFRD = 
5,10-methylene-tetrahydrofolate reductase deficiency, NKH = nonketotic hyperglycinemia, SOD = sulfite oxi-
dase deficiency, 3HBA = 3-hydroxybutyric aciduria, 3HMGD = 3-hydroxy-3-methylglutaryl coenzyme A lyase 
deficiency, TYRSN1 = tyrosinemia type 1.
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Confirmation of age-appropriate peak levels, 
detection of abnormal peak levels of metabo-
lites such as glycine and lactate, and loss of peak 
levels of substances such as creatine may help in 
identifying aminoacidopathies (6). Susceptibility-
weighted imaging is a high-spatial-resolution 
three-dimensional gradient-echo MR imaging 
technique involving phase postprocessing that 
increases the conspicuity of blood products, 
nonheme iron, and calcifications in the brain (7). 
Analysis of susceptibility-weighted phase images 
facilitates differentiation between intracranial 
calcifications and blood products.
Organic Acidemias
Organic acidemias are an important group of 
autosomal recessive inborn errors of metabolism. 
These errors are caused by defects in the interme-
diary metabolic pathways of carbohydrates, amino 
acids, and fatty acid oxidation, leading to the 
accumulation of organic acids in tissues and the 
subsequent excretion of these acids in urine (8).
Propionic Acidemia: OMIM 606054
Propionic acidemia is an autosomal recessive 
disorder caused by a deficiency in propionyl 
coenzyme A carboxylase, a biotin-requiring 
enzyme that catalyzes the conversion of propio-
nyl coenzyme A to methylmalonyl coenzyme A 
in the metabolic pathways of valine, isoleucine, 
methionine, threonine, and odd-chain fatty acids. 
Propionic acidemia has an estimated incidence of 
one in 100 000 to one in 150 000 individuals (9).
In up to 80% of affected children, propionic 
acidemia manifests within the first 3 months of 
life, with metabolic decompensation clinically 
characterized by vomiting, poor feeding, lethargy, 
and coma related to severe ketoacidosis, hyper-
ammonemia, hyperglycinemia, and decreased 
serum carnitine concentration (10). Propionic 
acidemia is increasingly being detected at new-
born screening before the onset of symptoms. 
Intermittent and chronic progressive forms of 
this disorder also exist.
The neuroimaging findings of propionic 
acidemia are nonspecific. In affected neonates, 
characteristic acute neuroimaging findings include 
acute brain swelling with diffuse signal intensity 
abnormality and decreased diffusion in the cerebral 
white matter (Fig 1) (12,13). The basal ganglia are 
reported to be normal during the neonatal period. 
In older patients with acute decompensation, a 
hyperintense signal at T2-weighted and fluid-atten-
uated inversion-recovery (FLAIR) MR imaging, as 
well as decreased diffusion, is typically seen in the 
basal ganglia—mainly the putamen and caudate 
nucleus—and less commonly seen in the substantia 
nigra and dentate nucleus (14). The cerebral and 
cerebellar cortices and the subcortical white matter 
also may show abnormal signal intensity and mild 
swelling. During the chronic stage, early abnormal 
(delayed) myelination and later cortical and white 
matter atrophy with signal intensity changes of the 
basal ganglia usually are seen. During the acute 
decompensation stage, 1H MR spectroscopy may 
reveal a decreased N-acetylaspartate (NAA) level, 
Table 2: Key Clinical Features of Pediatric Organic Acidemias and Aminoacidopathies
Clinical Feature Diseases*
Acute deterioration MMA, IVA, HSD, 5-oxoprolinuria, bKD, 3HMGD, GA1
Progressive deterioration L2HGA, 3HBA, Canavan disease
Recurrent deterioration PA, MMA, MSUD, IVA
Macrocephaly Canavan disease, GA1, L2HGA, D2HGA
Hypertonia MMA, IVA
Ischemic events PA, SOD, MOCD, HSD, CBSD, MTHFRD, 3HMGD
Ophthalmoplegia MMA, PA, D2HGA, biotidinase deficiency, GA1, Canavan disease
Lens dislocation SOD, MOCD, CBSD
Sensorineural hearing loss Biotidinase deficiency
Craniofacial dysmorphism D2HGA, SOD, MOCD, 3HBA
Breathing abnormalities NKH
Acute pancreatitis PA, MMA, IVA, MSUD, CBSD
Skin involvement PKU, biotidinase deficiency
Peculiar odor PKU (musty), IVA (sweaty feet), HSD (cat urine), MSUD (sweet syrup)
Lactic acidosis with hypoglycemia 3HMGD
Ketotic hypoglycemia βKD, IVA, PA, MMA
*βKD = β-ketothiolase deficiency, HSD = holocarboxylase synthetase deficiency, IVA = isovaleric acide-
mia, MMA = methylmalonic acidemia, MOCD = molybdenum cofactor deficiency, NKH = nonketotic 
hyperglycinemia, PA = propionic acidemia, PKU = phenylketonuria, SOD = sulfite oxidase deficiency.
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Figure 1. Propionic acidemia in a 4-day-old neonate who presented with poor feeding, lethargy, hy-
pothermia, and bradycardia, and had a markedly elevated blood ammonia level. (a) Axial T2-weighted 
MR image shows edema (arrow) surrounding the internal capsule and globi pallidi. (b) Coronal trace of 
diffusion-weighted image shows restricted diffusion (arrow) in the internal capsule and adjacent globi 
pallidi. (Reprinted, with permission, from reference 11.)
decreased glutamate and glutamine levels, and an 
increased lactate level (15,16). Finally, an increased 
frequency of intracranial hemorrhage has been 
reported in children with propionic acidemia (17).
Methylmalonic Acidemia: OMIM 251000
Methylmalonic acidemia is an autosomal reces-
sive disease caused by a deficiency in methyl-
malonyl coenzyme A mutase, an adenosylco-
balamin-requiring enzyme that catalyzes the 
conversion of l-methylmalonyl coenzyme A to 
succinyl coenzyme A in the metabolic pathways 
of valine, isoleucine, methionine, threonine, and 
odd-chain fatty acids (9). Methylmalonic acide-
mia can also be caused by defects in the adeno-
sylcobalamin-cobalamin biosynthetic pathway. 
This disease has an estimated incidence of one 
in 50 000 individuals (9).
The clinical manifestations of methylmalonic 
acidemia are highly variable, depending on the 
severity of the enzyme defect, although failure 
to thrive, developmental delay, megaloblastic 
anemia, and neurologic dysfunction are com-
mon findings. Severely affected patients usually 
present during the neonatal period with poor 
feeding, dehydration, increasing lethargy, em-
esis, and hypotonia after a short asymptomatic 
period. They may also have ocular abnormalities 
such as retinopathy and nystagmus. Like propi-
onic acidemia, methylmalonic acidemia is de-
tectable with newborn screening and therefore 
may be detected presymptomatically. Hyper-
ammonemia is a common feature of the severe 
early form of methylmalonic acidemia. Milder 
cases typically decompensate later during in-
fancy or during childhood, with hypoglycemia, 
acidosis, seizures, and lethargy.
The neuroimaging findings of methylmalonic 
acidemia are nonspecific. Characteristic acute 
neuroimaging findings in neonates with meth-
ylmalonic acidemia include diffuse T2-hyper-
intense brain swelling with matching reduced 
diffusivity (Fig 2) (18). Follow-up MR imaging 
examinations performed at a later patient age 
may reveal cortical and white matter volume 
loss, with thinning of the corpus callosum, ven-
triculomegaly, signal intensity abnormalities of 
the periventricular and subcortical white mat-
ter, and basal ganglia calcifications. The basal 
ganglia calcifications are best seen on computed 
tomographic or susceptibility-weighted MR im-
ages (19). Bilateral infarctions of the globus pal-
lidus may be seen at follow-up in approximately 
50% of patients with methylmalonic acidemia 
(Fig 3). Bilateral infarctions usually are slightly 
asymmetric and mainly involve the posterior 
portion of the globus pallidus. Tiny lacunar 
infarctions in the pars reticulata of the substan-
tia nigra also may be seen. 1H MR spectroscopy 
may reveal a decreased NAA concentration and 
a lactate level peak during acute decompensa-
tion. However, MR imaging findings may also 
appear unremarkable (19).
Isovaleric Acidemia: OMIM 243500
Isovaleric acidemia is an autosomal recessive 
disorder caused by a deficiency in the mitochon-
drial enzyme isovaleryl coenzyme A dehydroge-
nase. This deficiency leads to the accumulation 
of several metabolites (20). Isovaleric acidemia 
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has an estimated incidence of less than one in 
200 000 individuals (21).
Isovaleric acidemia classically manifests with 
two phenotypes: early (ie, neonatal or infantile) 
metabolic crises that often lead to coma and a 
later-onset chronic intermittent course of disease 
that occurs during childhood (20). The acute form 
occurs in newborns and infants who are healthy 
at birth but later, during the first postnatal days, 
exhibit vomiting, feeding refusal, listlessness, 
dehydration, and lethargy. Seizures may occur, and 
the odor of sweaty feet is characteristic. Progres-
sion to coma and often death occur in nontreated 
infants. Children who survive typically develop a 
chronic intermittent form of isovaleric acidemia, 
which is characterized by episodes of vomiting, 
acidosis with ketonuria, lethargy that can progress 
to coma, and a characteristic odor that is triggered 
by an upper respiratory infection or ingestion of 
protein-rich food. Children with isovaleric acide-
mia who survive the metabolic crises intact often 
have normal cognitive development. However, 
mild cognitive impairment can occur.
The neuroimaging literature on isovaleric 
acidemia is limited, and the neuroimaging findings 
are nonspecific. A hypointense signal in the globus 
pallidus bilaterally at T1-weighted MR imaging, 
as well as a hyperintense signal in the globus pal-
lidus bilaterally at T2-weighted and FLAIR MR 
imaging, has been reported (22). During the acute 
neonatal stage of this disease, T1-hypointense and 
T2-hyperintense signals in the supratentorial white 
matter may be seen without matching diffusion 
restriction (Fig 4a) (11). An increased frequency 
Figure 3. Methylmalonic acide-
mia in an 18-month-old girl with 
acute metabolic crisis. (a) Axial 
T2-weighted MR image shows 
hyperintense signal in the globus 
pallidus bilaterally. (b) Matching 
axial trace of diffusion-weighted 
image obtained during the acute 
metabolic crisis reveals bilateral re-
stricted diffusion in the globus pal-
lidus. (Reprinted, with permission, 
from reference 4.)
Figure 2. Methylmalonic acidemia in a 6-day-old term newborn who was small for gestational age 
and found to have acute encephalopathy and hyperammonemia. (a) Axial T2-weighted MR image 
shows mildly increased signal intensity (arrow) surrounding the posterior limb of the internal capsule. 
(b) Coronal trace of diffusion-weighted image reveals restricted diffusion (arrow) in the corticospinal 
tracts as they course through the posterior limbs of the internal capsule to the brainstem. (Reprinted, 
with permission, from reference 11.)
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of intracranial hemorrhage—seen as subarachnoid, 
intra- or periventricular, cerebellar, and diffuse 
petechial lesions in the white matter—has been 
reported with isovaleric acidemia (Fig 4b). Hem-
orrhage is best seen on susceptibility-weighted 
MR images and may result from various factors, 
such as brain edema due to the accumulation of 
abnormal organic acids, thrombocytopenia, and 
coagulopathy secondary to associated liver disease. 
This bleeding can also occur as a complication of 
anticoagulation therapy during hemofiltration to 
correct metabolic disturbances (17).
MCCD: OMIM 210200 and 210210
MCCD is an autosomal recessive disorder that 
affects the catabolic pathway of leucine. Biotin is a 
cofactor in this pathway. MCCD has an estimated 
incidence of one in 50 000 individuals (23).
Children with MCCD may present with a 
heterogeneous phenotype (24). Although many 
patients with MCCD remain asymptomatic, 
on rare occasion, affected patients become 
symptomatic during infancy or childhood, with 
episodes of vomiting, feeding difficulty, lethargy, 
hypotonia, hyperreflexia, hypoglycemia, meta-
bolic acidosis, and ketosis in the context of a 
mild infection or other stress.
The neuroimaging literature on MCCD is 
limited; this is probably because of the typically 
milder clinical manifestations compared with 
those of other organic acidemias. Neuroimag-
ing findings are nonspecific. During the acute 
phase, a hyperintense signal at T2-weighted and 
FLAIR MR imaging—with matching diffusion 
changes—may be seen bilaterally in the globi 
pallidi, thalami, cerebral peduncles, medulla 
oblongata, pons, inferior cerebellar peduncles, 
and periventricular white matter (25). Confluent 
and multifocal T2-hyperintense signal changes 
in the white matter may be the only neuro-
imaging findings (26). At follow-up, a rapid 
progression of gray and white matter atrophy 
associated with subdural hematomas is seen. 1H 
MR spectroscopy may reveal elevated levels of 
lactate, branched-chain amino acids, glutamine, 
and glutamate (25). However, in mildly symp-
tomatic or asymptomatic patients, neuroimaging 
findings are typically normal.
Multiple Carboxylase Deficiency
Multiple carboxylase deficiency refers to a group 
of biotin-responsive, autosomal recessive diseases 
with somewhat distinct but overlapping clini-
cal manifestations. There are two main types of 
multiple carboxylase deficiency: biotinidase and 
holocarboxylase.
Biotinidase Deficiency: OMIM 253260.—Biotini-
dase deficiency is typically a later-onset form of 
multiple carboxylase deficiency caused by a defi-
ciency in biotinidase activity that results in a lack 
of biotin recycling (27). The estimated incidence 
of biotinidase deficiency is one in 61 000 individu-
als. Because biotinidase deficiency can be detected 
with high sensitivity and specificity at newborn 
screening, it is often diagnosed and treated before 
the onset of clinical symptoms and radiologic 
abnormalities. Clinicians should be aware of the 
clinical manifestations of this deficiency when it is 
left untreated, given its highly treatable nature.
Figure 4. Isovaleric acidemia in a 13-day-old newborn who presented with lethargy, jitteriness, and 
a sweaty smell. (a) Axial T2-weighted MR image shows mildly increased signal intensity (arrow) of the 
white matter. (b) Axial T2*-weighted MR image shows small multifocal hemorrhages (arrow) in the cer-
ebellum. (Reprinted, with permission, from reference 11.)
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Children with biotinidase deficiency usually 
have lethargy, hypotonia, anorexia or vomiting, 
developmental delays, ataxia, and seizures—and 
can go into a state of coma—during the early to 
middle infancy period (27). Skin involvement is 
common and includes alopecia, rash, and mu-
cocutaneous candidiasis. Hearing loss and optic 
atrophy are potential important long-term compli-
cations. Some patients present with motor weak-
ness, spastic paresis, or loss of visual acuity during 
later childhood or adolescence.
The neuroimaging findings of biotinidase defi-
ciency in children are nonspecific. Cerebral cortex 
and white matter atrophy with secondary enlarge-
ment of the ventricular system and extra-axial 
CSF spaces is the most common finding (27,28). 
Diffuse or patchy signal intensity abnormalities of 
the cerebral white matter (frontoparietal region in 
particular) and cerebellar white matter in associa-
tion with restricted diffusion and subcortical cyst 
formation may be seen (28,29). In some children, 
a Leigh disease–like neuroimaging pattern with 
symmetric signal intensity abnormalities in the 
basal ganglia, medial thalami, dorsal midbrain, 
pons, and medulla may been seen (30). Signal 
intensity abnormality of the entire spinal cord at 
T2-weighted MR imaging, representing edema 
and/or demyelination and mimicking neuromyeli-
tis optica, also may be seen (29–31). Finally, 1H 
MR spectroscopy may reveal a lactate concentra-
tion peak and decreased NAA level (28). These 
findings may be entirely or partially reversible with 
early and adequate treatment (28).
Holocarboxylase Synthetase Deficiency: OMIM  
253270.—Holocarboxylase synthetase deficiency 
is a life-threatening early-onset form of multiple 
carboxylase deficiency that is caused by a defect 
in holocarboxylase synthase activity (32). The 
estimated incidence is one in 200 000 individu-
als. This disease leads to a combined enzyme 
deficiency that causes an accumulation of several 
organic acids, including lactic, 3-hydroxyisovale-
ric, 3-hydroxypropionic, and methylcitric acids.
The clinical symptoms of holocarboxylase syn-
thetase deficiency typically manifest within hours 
to a few weeks after birth and include irritability, 
lethargy, feeding problems, vomiting, tachypnea, 
and hypertonia or hypotonia. Without treatment, 
symptoms progress to intractable seizures and 
coma. Exfoliative dermatitis and hyperammone-
mia are commonly present.
The published literature on the neuroim-
aging findings of holocarboxylase synthetase 
deficiency is scant. Neuroimaging findings are 
nonspecific and typically include subependymal 
cysts, ventriculomegaly, and intraventricular 
hemorrhage that can be seen prenatally (33,34). 
However, some patients have normal neuroim-
aging findings (34).
b-Ketothiolase Deficiency: OMIM 203750
b-ketothiolase defiency is a rare organic acide-
mia that involves a common step in ketone body 
and isoleucine metabolism. It has an estimated 
incidence of one in 135 000 to one in 230 000 
individuals (35).
The spectrum of clinical symptoms in children 
with b-ketothiolase defiency is wide. The major-
ity of these children have intermittent episodes of 
ketoacidosis associated with vomiting, dyspnea, 
tachypnea, hypotonia, lethargy, and coma within 
the first 2 years of life (35). Children are typically 
well between the episodes.
The literature on the neuroimaging findings 
of b-ketothiolase defiency comprises only a few 
reports. A symmetric hypointense (at T1-weighted 
MR imaging) or hyperintense (at T2-weighted 
and FLAIR MR imaging) signal in the putamen 
(usually the posterior part) and/or globus pallidus 
bilaterally, with restricted diffusion, is the most 
common neuroimaging finding (36,37). In addi-
tion, a hyperintense signal of the dentate nuclei 
at T2-weighted and FLAIR MR imaging may be 
seen. 1H MR spectroscopy may reveal a lactate 
level peak with an occasional increase in the cho-
line concentration (38).
Canavan Disease: OMIM 271900
Canavan disease, also known as spongy degen-
eration of the brain, is an autosomal recessive 
disorder caused by a deficiency in aspartoacylase, 
which catalyzes the hydrolysis of NAA, leading 
to the accumulation of NAA (39). The estimated 
worldwide incidence is one in 100 000 individu-
als, with a higher incidence—one in 6400 to one 
in 13 500 individuals—in the Ashkenazi Jewish 
population. There is typically an increased concen-
tration of NAA in the urine.
Canavan disease manifests in infantile and 
juvenile (late-onset) forms (39). Infantile Canavan 
disease is the most common, and affected infants 
present within the first 6 months of life with 
hypotonia, poor head control, poor eye contact, 
macrocephaly, irritability, and absence of early 
milestones. Later, these children may develop 
spasticity, opisthotonus, and decerebrate or decor-
ticate posturing, and most of them die within the 
first 3 years of life. Children with late-onset Cana-
van disease may present with mild developmental 
delay, speech difficulties, and cognitive problems 
with neurologic regression.
The neuroimaging findings of Canavan disease 
are diagnostic. Macrocephaly is typically conspicu-
ous at neuroimaging. In children with infantile-
onset Canavan disease, conventional MR imaging 
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Figure 5. Canavan disease in a 6-month-old infant who presented with hypotonia, poor head control, absence of develop-
mental milestones, and macrocephaly. (a) Axial T2-weighted MR image shows diffuse high signal intensity in the white mat-
ter, absence of myelination in the internal capsules, and high signal intensity in the globi pallidi and thalami. (b) Single-voxel 
1H MR spectrum sampling the right parietal white matter (as shown on the inset) shows a marked increase in the NAA level. 
Cho = choline, Cr and Cr2 = creatine resonances.
sequences typically reveal diffuse symmetric areas 
of hypointense (on T1-weighted images) or hy-
perintense (on T2-weighted and FLAIR images) 
signal in the cerebral white matter, with predomi-
nant involvement of the subcortical white matter, 
which appears swollen, and partial sparing of the 
corpus callosum and internal capsule (Fig 5a) 
(40). During the course of the disease, the central 
periventricular white matter also becomes af-
fected, and white matter atrophy with compensa-
tory ventriculomegaly is typically seen at follow-
up. In addition, the globi pallidi are almost always 
involved, the thalami are often affected, and the 
caudate nuclei and putamina are typically spared 
(Fig 5a). Brainstem tracts, cerebellar white mat-
ter, and dentate nuclei also may be affected. 
The T2-weighted and FLAIR MR images ob-
tained in children with a less severe course of the 
disease may show only a mild hyperintense signal 
of the arcuate fibers, striatum, dentate nuclei, and 
dorsal brainstem (41). Diffusion-weighted and 
diffusion-tensor images show restricted diffu-
sion and low fractional anisotropy values in the 
affected white matter, which are most likely due 
to intramyelinic edema (42). The 1H MR spec-
trum in Canavan disease is pathognomonic and 
shows a markedly increased NAA peak level (Fig 
5b) in both mild and severe cases and during the 
neonatal period, with the remaining MR imaging 
findings usually being normal. The NAA peak 
level may decrease after gene therapy.
GA1: OMIM 231670
GA1 is an autosomal recessive disorder caused 
by a deficiency in glutaryl coenzyme A dehydro-
genase activity. It has an estimated incidence of 
approximately one in 100 000 individuals (43). 
Glutaryl coenzyme A dehydrogenase is a key 
enzyme in the degradation pathway for lysine, 
hydroxylysine, and tryptophan. Deficient glutaryl 
coenzyme A dehydrogenase activity results in the 
accumulation of glutarate, glutarylcarnitine 3-hy-
droxyglutarate, and glutaconate in tissue, blood, 
CSF, urine, and multiple organs. Increased gluta-
rate and 3-hydroxyglutarate levels may cause an 
imbalance in glutamatergic and γ-aminobutyric 
acid–mediated neurotransmission, and 3-hydrox-
yglutarate can cause excitotoxic cell damage me-
diated by the activation of N-methyl-d-aspartate 
receptors and result in striatal lesions (44). The 
diagnosis of GA1 is typically made on the basis of 
changes in organic acid levels and the acylcarni-
tine profile and confirmed with genetic analysis. 
Therapy—with carnitine supplementation and/
or a low-lysine diet—should be started as soon as 
suspicion for GA1 is raised.
Children with GA1 typically present between 
the ages of 3 and 18 months with acute-onset 
dystonia and dyskinesia after an acute illness 
such as febrile viral infection of the upper airway 
(43). After an acute encephalopathic crisis, the 
affected child usually loses motor and language 
skills, and severe dystonia affects the long-term 
outcome. Intellectual functions may be relatively 
unaffected. Milder cases of GA1 without enceph-
alopathic crises have been reported.
At MR imaging, symptomatic children have 
symmetric injury of the basal ganglia—the puta-
men and caudate nucleus in particular—whereas 
involvement of the globus pallidum is less common 
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(45,46). The basal ganglia are swollen during the 
acute phase (Fig 6) and become atrophic as the 
disease progresses. Putaminal changes seen at MR 
imaging are reliable predictors of long-term move-
ment disorders (45). In addition, abnormalities are 
often seen in the upper brainstem, with increased 
signal intensity of the substantia nigra, central 
tegmental tracts, tegmentum, dentate nuclei, and 
white matter at T2-weighted MR imaging. The 
white matter changes are usually patchy and scat-
tered and are mainly seen as small foci of gliosis 
in subcortical regions. Bilateral but not necessar-
ily symmetric enlargement of subarachnoid CSF 
spaces in the temporal fossa and, in particular, 
widening of the sylvian fissures due to opercular 
hypoplasia are characteristic of GA1 (Fig 7a, 7b).
With GA1, subdural hematomas can be seen 
in symptomatic and asymptomatic patients, even 
during the immediate postnatal period. These 
hematomas can occur, sometimes repeatedly, with 
minimal trauma, mimicking abusive head trauma. 
The hematomas are presumably related to the 
rupture of bridging veins in the presence of cere-
bral atrophy. Retinal hemorrhage also has been 
reported. Advanced neuroimaging techniques may 
help to facilitate the diagnostic workup. Restricted 
diffusion is usually seen in the basal ganglia and 
white matter during the acute metabolic crisis. 1H 
MR spectroscopy may reveal a mild increase in 
the lactate level during the acute phase, whereas 
the NAA level is typically decreased during the 
subacute and chronic phases.
L2HGA: OMIM 236792
L2HGA is an autosomal recessive disease caused 
by mutations in L2HGDH, the mitochondrial 
enzyme gene, which cause the accumulation of l-
2-hydroxyglutaric acid in urine, CSF, and plasma 
(47). The exact prevalence of L2HGA is unknown; 
about 150 cases have been published so far. An in-
creased incidence of brain tumors such as medul-
loblastoma has been reported (48). The diagnosis 
of L2HGA is made on the basis of an increase in 
the urinary excretion of 2-hydroxyglutaric acid 
without any other organic acid abnormality.
Children with L2HGA typically present with 
developmental delay, hypotonia, ataxia, and 
seizures within the 1st year of life (49). Mac-
rocephaly is mentioned in most reported cases 
in the literature, but it occurs in approximately 
half of the individuals with this disorder (50). 
The course of this disease is progressive, and af-
fected children usually develop spasticity, extra-
pyramidal movement disorders, and behavioral 
problems and experience a progressive decline in 
previously acquired skills.
The neuroimaging findings of L2HGA are 
diagnostic and highly consistent. High signal 
intensity in the cerebral white matter, pre-
dominantly involving the frontal and subcortical 
regions, which may appear swollen and be mul-
tifocal initially, is typically seen on T2-weighted 
and FLAIR MR images (Fig 8a) (49,50). The 
white matter signal intensity abnormalities later 
become more confluent; however, the periven-
tricular white matter, corpus callosum, posterior 
limb of the internal capsule, cerebellar white 
matter, and brainstem remain relatively spared. 
The dentate nuclei are consistently T2 hyperin-
tense (Fig 8b); usually the basal ganglia also are 
involved and the thalami are spared (50). Cer-
ebellar atrophy may occur. Diffusion-weighted 
and diffusion-tensor imaging results usually are 
unremarkable. 1H MR spectroscopy may reveal 
a mild decrease in the NAA level and an in-
creased myo-inositol level (51).
Figure 6. GA1 in a 7-month-old infant 
with acute-onset dystonia. (a) Axial T2-
weighted MR image shows swelling char-
acterized by increased volume and high 
signal intensity in the bilateral striatum 
and enlarged sylvian fissures secondary 
to opercular hypoplasia. (b) Axial trace 
of diffusion-weighted image shows re-
stricted diffusion in the striate nuclei dur-
ing the acute phase of disease. (Reprinted, 
with permission, from reference 4.)
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D2HGA: OMIM 600721 and 613657
D2HGA is a rare autosomal recessive disorder 
caused by a deficiency in the mitochondrial en-
zyme d-2-hydroxyglutarate dehydrogenase, which 
leads to the accumulation of d-2-hydroxyglutaric 
acid in urine, plasma, and CSF (52). The exact 
prevalence of D2HGA is unknown; about 80 cases 
have been published so far. Rarely, a combina-
tion of D2HGA and L2HGA occurs owing to 
SLC25A1 mutations. The diagnosis is made on the 
basis of increased urinary excretion of 2-hydroxy-
glutaric acid. However, this finding does not enable 
differentiation between L2HGA and D2HGA.
D2HGA can manifest as a severe disorder 
with a neonatal or early-infantile onset or as 
a milder disorder with a later onset (53). The 
severe phenotype is characterized by marked 
hypotonia, developmental delay, seizures, vision 
loss, cardiomyopathy, and facial dysmorphic 
features. A subtype of this disorder, D2HGA type 
II, also involves cardiomyopathy as a key feature. 
The phenotype of the mild form is variable, with 
developmental delay and hypotonia being the 
most common findings.
In contrast to the characteristic MR imaging 
findings of L2HGA, the neuroimaging findings 
of severe D2HGA in infants are less consistent. 
These findings typically include nonspecific 
imaging features such as a delayed or simplified 
gyral pattern, delayed myelination, subependymal 
germinolytic cysts, mild ventriculomegaly with 
predominant involvement of the posterior horns of 
the lateral ventricles, and enlargement of the extra-
axial CSF spaces with secondary subdural hemor-
rhage (Fig 9) (53,54). Follow-up images may show 
progression of gyral folding with development of 
Figure 7. GA1 and mild dyski-
netic movement disorder in an 
18-year-old woman. Axial T2-
weighted MR images show large 
asymmetric arachnoid cysts in the 
bilateral middle cranial fossae (a), 
with superior extension to the 
sylvian fissure on the right (b). In 
addition, bilateral high signal in-
tensity and atrophy are seen in the 
dorsal putamina, consistent with 
prior injury.
Figure 8. L2HGA in a 2-year-
old boy with macrocephaly, 
ataxia, and hypotonia. (a) Axial 
T2-weighted MR image shows in-
creased signal intensity in the sub-
cortical white matter, with sparing 
of the central deep white matter 
and corticospinal tracts. (b) Axial 
T2-weighted MR image shows bi-
lateral high signal intensity of the 
dentate nuclei.
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secondary and tertiary sulci. Myelination remains 
delayed, and patchy white matter signal intensity 
abnormalities may be seen. Multiple aneurysms 
of the cerebral arteries were found in one patient 
(55). In patients with mild D2HGA, germinolytic 
cysts and delayed myelination may be the only 
findings. Patients with combined D2HGA and 
L2HGA usually have neuroimaging findings simi-
lar to those in patients with severe D2HGA.
5-Oxoprolinuria: OMIM 260005
5-Oxoprolinuria, or pyroglutamic aciduria, is an 
autosomal recessive disorder that is caused by 
errors in the synthesis and degradation of glutathi-
one and results in the massive urine excretion of 
5-oxoproline (56). Fewer than 100 patients with 
this disease have been reported on so far.
The clinical manifestations of 5-oxoprolinuria 
may include metabolic acidosis, mental retardation, 
ataxia, spasticity, seizures, psychiatric disturbances, 
recurrent bacterial infections due to defective gran-
ulocyte function, and hemolytic anemia (56). The 
neuroimaging literature on 5-oxoprolinuria is based 
only on a few case reports that also include autopsy 
data. Neuroimaging findings may be normal or 
indicate cerebral atrophy over time (57,58).
3HBA: OMIM 236795
3HBA is probably an autosomal recessive valine 
metabolism disorder (59). Fewer than 15 cases 
have been reported to date. Children with 3HBA 
typically have hypotonia, seizures, failure to thrive, 
dehydration, episodes of ketoacidosis, lactic acide-
mia, and lethargy during the neonatal period (59). 
Dysmorphic facial features also may be seen.
The neuroimaging literature on 3HBA is based 
only on a few case reports. During the ketoacidotic 
episode, bilateral swelling and signal intensity 
abnormality of the putamina and caudate nucleus 
heads may be seen (60). In addition, single cases 
of cortical abnormalities such as lissencephaly 
and polymicrogyria, callosal dysgenesis, focal 
white matter signal intensity abnormality, ven-
triculomegaly, and cerebellar dysplasia have been 
reported (61,62).
3HMGD: OMIM 246450
3HMGD is an autosomal recessive organic 
aciduria caused by a deficiency in 3-hydroxy-
3-methylglutaryl coenzyme A lyase, a key enzyme 
in ketogenesis and leucine metabolism (63). The 
estimated incidence is less than one in 100 000 
individuals.
The majority of children with 3HMGD pres-
ent during the neonatal period—after a short 
symptom-free interval—with hypotonia, leth-
argy, seizures, vomiting, and dehydration. They 
may also have severe hypoketotic hypoglycemia. 
Acute encephalopathic crises with metabolic 
acidosis and hypoglycemia may recur, usually 
owing to noneating or infection, and result in 
permanent and severe neurologic compromise.
Neuroimaging findings include diffuse mild 
or multifocal, more severe foci of white matter 
signal intensity abnormality that typically spare 
the corpus callosum, subcortical arcuate fibers, 
and cerebellar white matter (64,65). In addi-
tion, signal intensity abnormalities of the basal 
ganglia (head of the caudate nuclei and anterior 
part of the putamina), dentate nuclei, and brain-
stem tegmentum may be seen. 1H MR spec-
troscopy can be diagnostic and reveal abnormal 
positive peaks at 1.3 and 2.4 ppm, which most 
likely represent 3-hydroxy-3-methylglutaryl 
coenzyme A lyase(64,65).
Aminoacidopathies
Aminoacidopathies are an important group of 
autosomal recessive inborn errors of metabo-
lism. They are caused by the deficiency in an 
enzyme or transporter involved in amino acid 
metabolism (66).
Phenylketonuria: OMIM 261600
Phenylketonuria is an autosomal recessive dis-
order with an incidence of one in 10 000 people 
in the general population of white individuals. 
However, it is more common in Turkey, Scot-
land, Czech Republic, Slovakia, Arabic popula-
tions, and persons of Yemenite Jewish ancestry 
(one in 2500 to one in 5000 people) (67). 
Phenylketonuria is caused by mutations in the 
PAH gene, which result in high values of phenyl-
alanine. The high phenylalanine values seem to 
be the cause of neurotoxicity.
Figure 9. D2HGA in a 5-day-old boy. Sagittal T1-
weighted MR image shows extensive parieto-occipi-
tal pachygyria and a subependymal cyst. (Reprinted, 
with permission, from reference 4.)
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In most patients, the diagnosis of phenylke-
tonuria is made at routine newborn screening 
in asymptomatic neonates (68). Children who 
maintain goal levels of plasma phenylalanine by 
means of dietary restriction of phenylalanine 
intake typically have normal cognitive develop-
ment. Nontreatment of classic phenylketonuria 
results in profound intellectual disability. Acute 
metabolic encephalopathy, a common feature of 
many organic acidurias and aminoacidopathies, 
does not occur with phenylketonuria. Children 
with phenylketonuria usually are healthy at birth 
and have normal early development, even if they 
are not treated. Over time, classically affected 
patients develop microcephaly, spasticity, tremor, 
and athetosis and will have seizures. Psychiatric 
and behavioral problems, including autistic be-
havior and attention deficit hyperactivity disor-
der, are common. Affected individuals may have 
lighter pigmentation, eczema, and a musty odor 
attributed to phenylacetic acid.
At neuroimaging, T2-weighted and FLAIR 
MR images may show a hyperintense signal in 
the periventricular white matter that may also af-
fect the subcortical white matter. This high signal 
intensity probably reflects hypomyelination in 
nontreated patients and intramyelinic edema in 
early-treated patients—findings that are best de-
picted on diffusion-weighted and diffusion-tensor 
images (Fig 10) (69,70). White matter changes 
seem to be reversible with adherence to a strict 
low-phenylalanine diet. Patient age and quality of 
dietary control were shown to have independent 
cumulative effects on the outcome of patients 
with white matter alterations (71). Over time, 
ventriculomegaly and secondary atrophy may 
develop. 1H MR spectroscopy may reveal a peak 
at 7.37 ppm, corresponding to phenylalanine.
Tyrosinemia Type 1: OMIM 276700
Tyrosinemia type 1 is an autosomal recessive 
disorder caused by a defect in fumarylacetoac-
etase; this enzyme has a key role in the pathway 
of degradation of tyrosine (72). As a result, toxic 
metabolites such as succinylacetone, maleylace-
toacetate, and fumarylacetoacetate are formed 
and cause severe disruption of the intracellular 
metabolism of the liver and kidneys. Tyrosin-
emia type 1 has an incidence of approximately 
one in 100 000 individuals.
A characteristic manifestation of tyrosinemia 
type 1 is acute liver failure that occurs during 
the first weeks or months of life and results in 
coagulation abnormalities, hemorrhage, ascites, 
and cirrhosis, with the risk of hepatocellular 
carcinoma later. Renal tubular disorder with 
Fanconi syndrome (ie, excess excretion of glu-
cose, bicarbonate, phosphates, uric acid, potas-
sium, and/or amino acids)—not to be confused 
with Fanconi anemia—also is characteristic of 
this disease (72). Some affected patients develop 
neurologic symptoms with pain, weakness (acute 
ascending motor neuropathy), and autonomic 
changes such as arterial hypertension.
Data on the neuroimaging findings in children 
with tyrosinemia type 1 are scant. Brain MR 
images obtained in one child showed T2-hyperin-
tense signal changes in the globus pallidus (73). 
In another reported case, diffusion-weighted im-
ages showed restricted diffusion in the centrum 
semiovale and corticospinal tracts (74).
MSUD: OMIM 248600
MSUD is an autosomal recessive defect in the 
catabolism of branched-chain amino acids (ie, 
leucine, isoleucine, and valine). It is caused 
by mutations in any of the components of the 
Figure 10. Phenylketonuria in a 17-year-
old girl. (a) Axial FLAIR MR image shows 
increased signal intensity (arrow) of the 
periventricular white matter. (b) Match-
ing axial trace of diffusion-weighted im-
age shows high signal intensity (arrow) 
of the periventricular white matter, rep-
resenting restricted diffusion and intra-
myelinic edema. (Reprinted, with permis-
sion, from reference 4.)
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mitochondrial branched-chain a-keto acid 
dehydrogenase complex (75).
In its classic form, MSUD manifests at the 
end of the 1st week of life, with severe neonatal 
encephalopathy, poor feeding, and vomiting. Dys-
tonia (rhythmic boxing and cycling movements 
of the limbs), opisthotonic posturing, fluctuating 
ophthalmoplegia, and seizures follow (76). MSUD 
can be detected at newborn screening to facilitate 
presymptomatic initiation of therapy. Early detec-
tion is critical, as initiation of therapy within the 
first 5 days of life is associated with an improved 
neurodevelopmental outcome (77). 
An odor similar to that of maple syrup or burnt 
sugar in the cerumen at 24–48 hours of life or in 
the urine during the latter part of the 1st week of 
life suggests a diagnosis of MSUD. The diagnosis 
can be confirmed by detection of increased values 
of branched-chain amino acids in blood or urine 
(76). However, some affected children present for 
medical attention later—at 5 months to 2 years of 
age—with episodes of neurologic decompensation 
characterized by ataxia, disorientation, and altered 
behavior. The crises associated with the intermit-
tent form of MSUD are usually triggered by infec-
tion or high protein intake.
The neuroimaging findings of MSUD—the 
characteristic pattern of edema at diffusion-
weighted imaging in particular—are diagnostic. 
Two types of brain edema can be seen with MSUD: 
intramyelinic edema and vasogenic edema. Intra-
myelinic edema is the intense form that affects the 
myelinated white matter (cerebellar white matter, 
dorsal brainstem, cerebral peduncles, posterior limb 
of the internal capsule, and perirolandic cerebral 
white matter), and the thalami and globi pallidi, 
both of which have a high density of myelinated 
fibers. Intramyelinic edema has the typical pattern 
of edema related to MSUD: high signal intensity on 
T2-weighted and diffusion-weighted MR images, 
low signal intensity on T1-weighted MR images, 
and decreased ADC and fractional anisotropy val-
ues (Fig 11) (78–81). 
Intramyelinic edema is thought to be caused 
by energy failure that results in decreased so-
dium-potassium adenosine triphosphatase activ-
ity due to the accumulation of branched-chain 
keto acids. The accumulation of water molecules 
between the myelinic lamellae results in decom-
paction and splitting of the myelin layering. The 
resulting myelin instability and ongoing fiber 
destruction, as indicated by decreased fractional 
anisotropy values, can be detected at diffusion-
tensor imaging (80,81). Delayed myelination 
and white matter atrophy are possible long-term 
sequelae. The intramyelinic edema may regress, 
but it frequently persists after initiation of 
therapy (80). 
In addition to intramyelinic edema, a super-
imposed vasogenic edema involving the unmy-
elinated brain structures may be observed. This 
second type of edema is due to blood-brain barrier 
disruption that causes a global increase in water in 
the extracellular spaces and is present only during 
acute metabolic decompensation or crisis (80,81). 
The 1H MR spectroscopic findings of MSUD 
include a lactate level peak (ie, anaerobic gly-
colysis due to energy failure) and a peak at 0.9 
ppm representing branched-chain amino acids 
and keto acids (78). These peaks may be absent 
in newborns who have undergone urgent dialysis 
and/or hemofiltration before MR imaging and/or 
1H MR spectroscopy.
Nonketotic Hyperglycinemia:  
OMIM 605899
Nonketotic hyperglycinemia, or glycine encepha-
lopathy, is a rare autosomal recessive disorder 
that is caused by a defective glycine cleavage 
system. This disorder leads to the accumulation 
of large amounts of glycine in body fluids and 
tissues and subsequent central nervous system 
toxicity (82). The neurotoxicity of glycine seems 
to be related to excitatory and inhibitory neuro-
nal effects on glycine and N-methyl-d-aspartate 
receptors in the telencephalon and brainstem–
spinal cord complex, respectively, and a distur-
bance in myelin proteins (83). The incidence of 
nonketotic hyperglycinemia is estimated to be 
one to nine in 1 000 000 individuals.
The majority of patients with nonketotic hy-
perglycinemia present during the neonatal period. 
Newborns typically present during the first 2 days 
of life with progressive lethargy, hypotonia, and 
myoclonic jerks rapidly evolving into apnea, coma, 
and often death (82). Hiccups, which may have a 
prenatal onset, and abnormal ocular movements 
are additional symptoms. The majority of surviv-
ing infants have profound intellectual disabilities 
and intractable seizures. Neonatal electroencepha-
lographic results are abnormal in at least 90% 
of cases and usually show a burst-suppression 
pattern. The diagnosis of nonketotic hyperglycin-
emia is established by an increase in CSF glycine 
concentration and an increased CSF glycine–to–
plasma glycine ratio, with the CSF and plasma 
glycine concentrations simultaneously sampled.
The neonatal neuroimaging findings include 
structural and white matter abnormalities. Agen-
esis or dysgenesis of the corpus callosum is the 
most common structural abnormality related to 
nonketotic hyperglycinemia and, when associated 
with the clinical manifestations, is suggestive of 
the diagnosis (84). In addition, hypoplasia of the 
cerebellar vermis—the inferior part in particu-
lar—has been reported (84). The myelinated 
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Figure 11. MSUD in a 10-day-old neonate with encephalopathy, poor feeding, vomiting, and rhythmic boxing and cycling 
movements of the limbs. (a) Axial T2-weighted MR images show hyperintense signal and swelling of the cerebellar white matter, 
dorsal pons, corticospinal tracts in the basis pontis, midbrain, posterior limb of the internal capsule, thalami, and central corona 
radiata. (b, c) Matching axial traces of diffusion-weighted images (b) and ADC maps (c) show high signal intensity and low ADC 
values, representing restricted diffusion, in the same regions of the brain. (Reprinted, with permission, from reference 11.)
white matter is affected and appears T2 hyperin-
tense (Fig 12a), and the degree of involvement is 
best seen on diffusion-weighted images (84,85). 
Restricted diffusion in the myelinated white 
matter tracts is indicated by matching low ADC 
values and is due to myelin vacuoles secondary to 
the splitting of the myelin sheets (Fig 12b) (85). 
Sequential neuroimaging findings indicate 
resolution of the restricted diffusion in the my-
elinated white matter (86). This suggests that the 
myelination itself is not delayed and is probably 
due to coalescence of the myelin vacuoles. Frac-
tional anisotropy values in the myelinated white 
matter have been reported to be normal initially 
and subsequently decrease, indicating axonal loss 
(86). With nonketotic hyperglycinemia, 1H MR 
spectroscopy will reveal a striking increase in the 
glycine peak level at 3.55 ppm (Fig 12c) (87,88). 
Because the glycine peak cannot be distinguished 
from the normal myo-inositol peak on short-echo 
MR spectra, the elevation in glycine concentration 
might be best evaluated by using long-echo 1H 
MR spectra. With measurement of glycine concen-
trations, 1H MR spectroscopic findings may not 
only suggest the diagnosis of nonketotic hypergly-
cinemia but also be used to monitor the effects of 
therapeutic interventions.
Homocystinuria
Homocysteine is a key product in the catabolism 
pathway of methionine. Homocystinuria may be 
caused by the malfunction of three enzymes: cysta-
thionine b-synthase, methionine synthase, and 
methylene tetrahydrofolate reductase.
CBSD: OMIM 236200.—CBSD, or classic ho-
mocystinuria, is an autosomal recessive disorder 
that results in impaired synthesis of cystathio-
nine and abnormal accumulation of homocys-
teine, methionine, and other metabolites (89). 
The estimated incidence is approximately one to 
nine in 100 000 individuals.
CBSD is a multisystem disease characterized by 
intellectual disability, lens dislocations and mal-
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Figure 12. Nonketotic hyperglycinemia in a 5-day-old neonate who presented with severe 
seizures. (a) Axial T2-weighted MR image shows diffuse swelling and high signal intensity of 
the white matter. (b) Coronal ADC map reveals areas of low ADC value (arrow) in the cor-
ticospinal tracts, representing restricted diffusion. In addition, the “bull’s head” appearance 
of the ventricular system suggests agenesis or severe hypogenesis of the corpus callosum. 
(c) Short echo time (echo time, 32 msec) water-suppressed 1H MR spectra from the basal 
ganglia show an elevated glycine peak level (arrow) at 3.55 ppm. (Reprinted, with permission, 
from reference 11.)
formations, occlusive vascular events, and skeletal 
deformities (89). Intellectual disability is the most 
common neurologic manifestation; however, 
the spectrum of cognitive function ranges from 
normal cognitive function to profound intellectual 
disability. In addition, psychiatric problems, sei-
zures, and/or extrapyramidal signs may be present. 
Thromboembolic events secondary to hypercoag-
ulability are an important cause of morbidity and 
mortality, and they may cause occlusive periph-
eral venous and arterial diseases, cerebrovascular 
events, and myocardial infarction.
The neuroimaging findings of CBSD include 
multiple cortical-subcortical infarctions of differ-
ent ages in the cerebral and cerebellar hemispheres 
(90). Venous infarction may be seen secondary to 
dural sinus thrombosis (91). Diffuse white mat-
ter signal intensity changes also may be observed 
and suggest demyelination (92). MR angiography 
and MR venography may be helpful in detecting 
occlusive disease of large cerebral arteries and in-
tracranial dural sinuses. In addition, T2-weighted 
MR images may show lens dislocation in the form 
of an abnormal position of the hypointense lens 
within a hyperintense vitreous chamber. If seen, 
this feature is highly suggestive of CBSD.
MTHFRD: OMIM 236250.—MTHFRD is an 
autosomal recessive disorder that is caused by 
mutations in the MTHFR gene. This disorder 
is characterized by abnormal intracellular folic 
acid metabolism, which results in methyltetra-
hydrofolate deficiency and consequently homo-
cystinuria and hypomethioninemia (93). The 
clinical manifestations vary with enzyme func-
tion and include developmental delay, motor 
and gait abnormalities, seizures, and psychiatric 
disorders (93).
In children who have MTHFRD, neuroimag-
ing reveals abnormalities of the cerebral white 
matter that may be multifocal or diffuse; involve 
particularly the corpus callosum, external and 
extreme capsules, and anterior limb of the in-
ternal capsule; and may represent demyelination 
(94). The globi pallidi may have abnormal T2 
signal intensity. Areas of vascular infarction are 
usually seen and have restricted diffusion during 
the acute phase. A decreased NAA peak level at 
1H MR spectroscopy has been reported (95).
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Sulfite Oxidase Deficiency
Sulfite oxidase deficiency can occur in isolation 
(OMIM 272300)—in about 25% of cases—or in 
association with xanthine dehydrogenase defi-
ciency as part of molybdenum cofactor deficiency 
(OMIM 252150) (96,97). Sulfite oxidase is 
located in the mitochondrial intermembranous 
space and is involved in the transfer of electrons 
from sulfites into the electron transport chain.
Sulfite oxidase deficiency and molybdenum 
cofactor deficiency manifest during the first days 
of life, with seizures, feeding difficulties, and 
vomiting. Facial dysmorphism may be present, 
and ectopia lentis can appear later.
MR images initially show extensive bilateral 
abnormal signal intensity, suggesting edema of 
the gray and white matter with cytotoxic edema 
(Fig 13) (98–100). The frontal and temporal 
cortices and the thalami may be spared. At early 
follow-up, the edema is decreased and curvilinear 
areas of reduced signal intensity appear at the 
gray matter–white matter junction, suggesting 
hemorrhagic deposits and laminar necrosis (98).
The final stage of sulfite oxidase deficiency 
is characterized by rapid development of exten-
sive cystic leukomalacia, which may collapse 
(98–100). In addition, the cortex is globally atro-
phic, and areas of abnormal signal intensity are 
present bilaterally in the basal ganglia, internal 
capsule, and centrum semiovale. The cerebellum 
may be hypoplastic. 1H MR spectroscopy reveals 
increased lactate and choline levels, elevated glu-
tamine and glutamate levels (due to the inhibi-
tion of glutamate dehydrogenase by sulfites), and 
a reduced NAA level, as well as elevated peaks in 
the levels of several other metabolites that may 
have accumulated, including taurine at 3.42 and 
3.24 ppm, S-sulfocysteine at 3.61 ppm, and cys-
teine at 2.92 and 2.97 ppm (99,100).
The clinical and neuroimaging findings of 
sulfite oxidase deficiency and hypoxic-ischemic 
injury are similar, so it is not surprising that 
most cases of sulfite oxidase deficiency are ini-
tially misdiagnosed as hypoxic-ischemic injury 
(97). However, there are important differences: 
Newborns with hypoxic-ischemic injury usually 
stabilize 1–2 weeks after they are born, whereas 
those with sulfite oxidase deficiency do not 
show improvement or stability. With hypoxic-
ischemic injury, the caudate nucleus is rarely 
affected, whereas with sulfite oxidase deficiency, 
it is always involved (99). In patients with sulfite 
oxidase deficiency, as compared with those who 
have hypoxic-ischemic injury, the peak choline 
level at 1H MR spectroscopy is increased rather 
than reduced (100).
Conclusion
Organic acidemias and aminoacidopathies in-
clude a variety of inborn errors of metabolism that 
are caused by defects in intermediary metabolic 
pathways of carbohydrates, amino acids, and fatty 
acid oxidation. These defects lead to the accumu-
lation of organic acids and amino acids in body 
tissues and organs, including the brain. Several 
organic acidemias and aminoacidopathies manifest 
as acute encephalopathy during the neonatal–
early infantile period. Although metabolic and/or 
genetic laboratory tests are needed to confirm the 
diagnosis, the results of careful pattern recognition 
at neuroimaging (Table 3)—especially with inte-
gration of conventional and advanced MR imaging 
techniques—may suggest the diagnosis and help 
guide management. Imaging findings also help to 
distinguish organic acidemias and aminoacidopa-
thies from more common disorders with similar 
clinical manifestations. Furthermore, advanced 
neuroimaging techniques can be used to clarify 
Figure 13. Molybdenum cofac-
tor deficiency in a 4-day-old neo-
nate who presented with severe 
seizures. (a) Axial T2-weighted 
MR image shows swollen gyri and 
diffusely increased signal intensity 
of the cortex, white matter, and 
deep gray matter structures. There 
is loss of sulci due to gyral swell-
ing (arrow). (b) Axial ADC map 
shows areas of low ADC value (ar-
row), indicating restricted diffu-
sion of the entire cerebral cortex. 
(Reprinted, with permission, from 
reference 11.)
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disease mechanisms and, in cases of selected disor-
ders, have the potential to serve as biomarkers for 
monitoring therapy response.
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